摘要
目的探讨替莫唑胺联合细胞因子诱导的杀伤细胞(CIK)免疫疗法治疗恶性脑胶质瘤的疗效。方法将恶性脑胶质瘤78例患者根据治疗方法分为替莫唑胺组51例和联合治疗组27例,替莫唑胺组给予替莫唑胺治疗,联合治疗组给予替莫唑胺和CIK联合治疗,比较两组患者疗效、卡氏行为状态(KPS)评分、癌痛数字评分量表(NRS)评分、治疗后1年及2年的生存率、复发情况及不良反应。结果联合治疗组患者完全缓解率、部分缓解率、有效率、KPS评分均高于替莫唑胺组(均P<0.05),治疗后癌痛NRS评分低于替莫唑胺组(P<0.05),替莫唑胺组血小板减少率高于联合治疗组(P<0.05),但两组患者1年、2年生存率及复发率比较,差异均无统计学意义(均P>0.05)。结论 CIK免疫疗法联合替莫唑胺可以提高恶性脑胶质瘤患者的疗效,延缓复发,且不良反应较少。
Objective To observe the effect of temozolomide combined with cytokine-induced killer（CIK） immunotherapy on malignant glioma. Methods A total of 78 patients with malignant glioma were enrolled as subjects,and were divided into temozolomide group（51 cases） and combined therapy group（27 cases） according to the therapeutic approaches.The temozolomide group was treated with temozolomide,and the combined therapy group with temozolomide and CIK.The efficacy,Karnofsky Performance Status（KPS） score,and Numerical Rating Scale（NRS） score for cancer-induced pain,as well as the survival rate,relapse rate and adverse reactions at 1 and 2 years after treatmen,were compared between the two groups. Results The complete response rate,partial response rate,response rate and KPS score in the combined therapy group were higher than those in the temozolomide group（all P 〈0.05）,after treatment,the NRS score for cancer-induced pain was lower in the combined therapy than that in the temozolomide group（ P 〈0.05）,the thrombocytopenia rate in the temozolomide group was higher than that in the combined therapy group（ P 〈0.05）,but no significant difference was found in the 1-,2-year survival rate or relapse rate between the two groups（all P 〉0.05）. Conclusion CIK immunotherapy combined with temozolomide can improve the efficacy on patients with malignant glioma,delay the relapse,and achieve few adverse reactions.
作者
陈鹏宇
CHEN Peng-yu(Department of Internal Medicine,Wuchang Hospital of Wuhan,Wuhan 430063,China)
出处
《广西医学》
CAS
2018年第11期1196-1199,共4页
Guangxi Medical Journal
